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ABSTRACT Genetic approaches in Drosophila have successfully identified many genes involved in regu-
lation of growth control as well as genetic interactions relevant to the initiation and progression of cancer
in vivo. Here, we report on large-scale RNAi-based screens to identify potential tumor suppressor genes that
interact with known cancer-drivers: the Epidermal Growth Factor Receptor and the Hippo pathway tran-
scriptional cofactor Yorkie. These screens were designed to identify genes whose depletion drove tissue
expressing EGFR or Yki from a state of benign overgrowth into neoplastic transformation in vivo. We also
report on an independent screen aimed to identify genes whose depletion suppressed formation of
neoplastic tumors in an existing EGFR-dependent neoplasia model. Many of the positives identified here
are known to be functional in growth control pathways. We also find a number of novel connections to Yki and
EGFR driven tissue growth, mostly unique to one of the two. Thus, resources provided here would be useful
to all researchers who study negative regulators of growth during development and cancer in the context of
activated EGFR and/or Yki and positive regulators of growth in the context of activated EGFR. Resources
reported here are available freely for anyone to use.
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Studies in genetic models of tissue growth have identified networks of
signaling pathways that cooperate to control growth during animal
development (reviewed in (Harvey et al. 2013; Richardson and
Portela 2017). Normal tissue growth involves controlling the rates
of cell proliferation and cell death, as well as cell size, cell shape, etc.
Signaling pathways mediate hormonal and neuroendocrine regulation
of growth, which depend on nutritional status. Cell interactions also
contribute to coordinating growth of cells within a tissue.
Growth regulatory pathways include both positive and negative
elements to allow for feedback regulation. These feedback systems
confer robustness to deal with intrinsic biological noise, and with a
fluctuating external environment (Herranz and Cohen 2010). They
also provide the means for different regulatory pathways to interact
(Ren et al. 2010; Herranz et al. 2012a; Reddy and Irvine 2013). In the
context of tumor formation, this robustness is reflected in the
difficulty in generating significant misregulation of growth - a twofold
change in expression of many growth regulators seldom has a sub-
stantial effect on tissue size in Drosophila genetic models. More
striking is the difficulty in transitioning from benign overgrowth
to neoplasia: hyperplasia does not normally lead to neoplasia without
additional genetic alterations (e.g., (Huang et al. 2005; Herranz et al.
2012b 2014).
Cancers typically show mis-regulation of multiple growth regu-
latory pathways. Mutational changes and changes in gene expression
status contribute to driving cell proliferation, overcoming cell death
and cellular senescence, as well as to allowing cells to evade the
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checkpoints that normally serve to eliminate aberrant cells. These
changes alter the normal balance of cellular regulatory mechanisms,
from initial cellular transformation through disease progression
(Stratton 2011; Alexandrov et al. 2013). For many tumor types,
specific mutations have been identified as potent cancer drivers, with
well-defined roles in disease (Kandoth et al. 2013; Zehir et al. 2017).
However, most human tumors carry hundreds of mutations, whose
functional relevance is unknown. The spectrum of mutation varies
from patient to patient, and also within different parts of the same
tumor (McGranahan and Swanton 2017). Evidence is emerging that
some of these genetic variants can cooperate with known cancer
drivers during cellular transformation or disease progression. The
mutational landscape of an individual tumor is likely to contain
conditional oncogenes or tumor suppressors that modulate impor-
tant cellular regulatory networks.
Sequence-based approaches used to identify cancer genes favor
those with large individual effects that stand out from the ‘back-
ground noise’ of the mutational landscape in individual cancers
(Stratton 2011; Alexandrov et al. 2013). In vivo experimental ap-
proaches are needed to assign function to candidate cancer genes
identified by tumor genome sequencing, and to identify functionally
significant contributions of genes that have not attracted notice in
genomics studies due to low mutational frequency, or due to changes
in activity not associated with mutation. In vivo functional screens
using transposon mutagenesis of the mouse genome have begun to
identify mutations that cooperate with known cancer driver muta-
tions, such as K-Ras, in specific tumor models (Copeland and Jenkins
2010; Pérez-Mancera et al. 2012; Takeda et al. 2015). Genetic
approaches using Drosophila models of oncogene cooperation have
also been used to identify genes that act together with known cancer
drivers in tumor formation (Brumby and Richardson 2003; Pagliarini
and Xu 2003; Wu et al. 2010; Brumby et al. 2011; Herranz et al. 2012b
2014; Eichenlaub et al. 2016; Richardson and Portela 2017; Song et al.
2017). The simplicity of theDrosophila genome, coupled with the ease
of large-scale genetic screens and the high degree of conservation of
major signaling pathways with humans, make Drosophila an in-
teresting model to identify novel cancer genes and to study the
cellular and molecular mechanisms that underlie tumor formation
in vivo (reviewed in (Gonzalez 2013; Herranz et al. 2016; Sonoshita
and Cagan 2017; Richardson and Portela 2018).
In Drosophila, overexpression of the Epidermal Growth Factor
Receptor, EGFR, or Yorkie (Yki, the fly ortholog of the YAP onco-
protein) cause benign tissue over-growth (Huang et al. 2005; Herranz
et al. 2012a 2014). Combining these with additional genetic alter-
ations can lead to neoplastic transformation and eventually metas-
tasis (Herranz et al. 2012b 2014; Eichenlaub et al. 2016, 2018; Song
et al. 2017). Here, we report results of large-scale screens combining
UAS-RNAi transgenes with EGFR or Yki expression to identify
negative regulators of these growth regulatory networks that can
lead to aggressive tumor formation in vivo. We also performed an
independent screen to identify factors that could suppress EGFR-
driven neoplasia. These screens have identified an expanded genomic
repertoire of potential tumor suppressors that cooperate with EGFR
or Yki.We have also identified few positive regulators of growth in the
context of activated EGFR. Interestingly, there was limited overlap
among the genes that cooperated with EGFR and those that cooper-
ated with Yki. Gene intractome analysis and analyses of cancer
databases for human orthologs of positives of these screens suggest
that a large number of them have strong correlations to many
clinical parameters. The output of this screen would, therefore, be
useful to all researchers who study negative regulators of growth
during development and cancer in the context of activated EGFR and/
or Yki. Resources reported here are freely available for anyone to use.
MATERIALS AND METHODS
RNAi Screens
The KK transgenic RNAi stock library was obtained from the Vienna
Drosophila RNAi Center (www.vdrc.at; also listed in Table S1)
carrying inducible UAS-RNAi constructs on Chromosome II. For
each cross, 5 males from the KK transgenic RNAi stock were crossed
separately to 10-15 virgins from each of the following three driver
stocks (see Supplemental Fig. S1A for the schematics of fly stocks): w,
ap-Gal4, UAS-GFP/CyO; UAS-Yki, tub-Gal80ts/TM6B (Yki driver;
Song et al. 2017); w; ap-Gal4, UAS-GFP/CyO; UAS-EGFR, tub-
Gal80ts/TM6B (EGFR driver; Herranz et al. 2012b); and w; ap-Gal4,
UAS-GFP/CyO; and w; ap-Gal4, UAS-GFP, Socs36ERNAi/CyO;
UAS-EGFR, tub-Gal80ts/TM6B (EGFR driver +SOCS36ERNAi).
The combination of UAS-EGFR and UAS- SOCS36ERNAi inducing
tumorous growth is reported in Herranz et al. (2012b).
Virgin female flies were collected over 4-5 days and stored at 18
in temperature-controlled incubators on medium supplemented with
dry yeast, prior to setting up crosses. Virgin females weremated to KK
stock males (day 1) and the crosses were stored at 18 for 4 days to
provide ample time for mating before starting the timed rearing
protocol used for the screen. On day 5, the crosses were transferred
into new, freshly yeasted vials for another 3 days at 18. On day 8, the
adult flies were discarded, and larvae were allowed to develop until
day 11, at which time the vials were moved to 29 incubators to
induce Gal4 driver activity. Crosses were aged at 29 for a further
8-9 days, after which larvae were scored for size and wing disc
overgrowth phenotypes for Yki and EGFR driver screen crosses.
Flies were scored for suppression of the tumor phenotype for the
EGFR driver +SOCS36ERNAi crosses (see Supplemental Fig. S1B for
the screen workflow).
In order to verify the integrity of the driver stocks during the
course of the screen, we examined their expression patterns in
conjunction with setting up screen crosses each week. For each
driver, 2-3 of the bottles used for virgin collection were induced
at 29 for 24 hr and analyzed using fluorescence microscopy for
apterous-Gal4 specific expression in wandering 3-instar larvae (see
Supplemental Fig. S2 for larval images of quality control). Any batch
that showed tumorous growth on its own without a cross with
KK-RNAi line (in case of SOCS stocks, if the batch didn’t show
tumorous growth) were discarded and new batches were made from
the original clean stock.
Positive hits form the initial screen were retested by setting up 2 or
more additional crosses. The hits were scored as verified if 2 out of
3 tests scored positive. Wandering third instar larvae of confirmed
positives were imaged and documented using fluorescencemicroscopy.
Genomic DNA PCR 40D landing site occupancy test
Genomic DNA from a select number of Drosophila KK transgenic
RNAi library stocks was isolated following a protocol available at the
VDRC (www.vdrc.at). The presence or absence of the KK RNAi
transgene at the 40D insertion site on the second chromosome was
determined by multiplex PCR using the following primers:
40D primer (C_Genomic_F): 59-GCCCACTGTCAGCTCTCAAC-39
pKC26_R: 59-TGTAAAACGACGGCCAGT-39
pKC43_R: 59-TCGCTCGTTGCAGAATAGTCC-39
PCR amplification was performed using GoTaq G2 Hot Start
Green Master Mix kit (Promega) in a 25 mL standard reaction mix
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and the following program: initial denaturation at 95 for 2 min,
followed by 33 cycles with denaturation at 95 for 15 sec, annealing
at 58 for 15 sec and extension at 72 for 90 sec. One final
extension reaction was carried out at 72 for 10 min. Reactions
were stored at -20 prior to gel loading. PCR using these primers
generate an approximately 450 bp product in case of a transgene
insertion or a 1050 bp product in case of no transgene insertion
site at 40D.
Screen database
Results from the three screening projects were added to a screen
management database, http://www.iiserpune.ac.in/rnai/, including
images of positive hits and background information such as RNAi
line ID, corresponding gene information from the Flybase etc. The
database was developed by Livetek Software Consultant Services
(Pune, Maharashtra, INDIA).
Pathway and gene set enrichment analysis
Gene set enrichment analysis was performed using genes that upon
down regulation induced tumor formation (EGFR, YKI background)
or suppressed tumor formation (EGFR+SOCS background). For
D. melanogaster enrichment analysis all D. melanogaster protein
coding genes were used as the “gene universe” together with organism
specific datasets. For human ortholog enrichment analysis all hu-
man protein coding genes were used as the “gene universe” together
with organism specific datasets. The algorithm packages and data-
bases used in analysis are listed in Supplemental Tables S2 and
S3. Unless otherwise specified, pathway databases included in these
packages were used. The KEGG database was downloaded di-
rectly from source on 10.10.2018. Organ system specific and disease
related pathway maps were excluded from this analysis. Minimum
and maximum number of genes per pathway or gene set, significant
criteria, minimum enriched gene count and annotated gene counts
for each test and database are indicated in Supplemental Tables S2
and S3. GO results were filtered for level.2, to eliminate broad high-
level categories and ,10 to minimize duplication among subcate-
gories. A representative term was selected in the cases were identical
set of genes mapped to multiple terms within the same database. After
filtering, the top 10 terms from each database were used for clustering
analysis.
Pathway and gene set enrichment analysis results were visualized
as enrichment map with appropriate layout based on gene overlap
ration using igraph. Gene overlap ratio was set as edge width. Edges
with low overlap were deleted, filtering threshold was based on a
number of “terms” in the results table – from 0 to 50 by 10; increasing
filtering thresholds from 0.16 to 0.26 by 0.2. Clusters were detected
using “Edge betweenness community” algorithm. Similar biological
processes were color-coded.
R packages
clusterProfiler (3.8.1) - (Yu et al. 2012).
ReactomePA (1.24.0) - (Yu and He 2016).
http://pubs.rsc.org/en/Content/ArticleLanding/2015/MB/
C5MB00663E.
graphite (1.26.1) - Sales G, Calura E, Romualdi C (2018). graphite:
GRAPH Interaction from pathway Topological Environment. R
package version 1.26.1.
igraph (1.2.2) - Csardi G, Nepusz T: The igraph software package
for complex network research, InterJournal, Complex Systems 1695.
2006. http://igraph.org
Database references
KEGG – (Kanehisa et al. 2016, 2017).
REACTOME – (Fabregat et al. 2018)
Panther – (Thomas et al. 2003)
GO – (Ashburner et al. 2000).
STRING interaction maps
STRING v10 is a computational tool for protein interaction network
and pathway analysis (Szklarczyk et al. 2017)), to identify significant
functional clustering among the candidate genes. STRING builds
interaction maps by combining experimental data (including protein
interaction data) with information about functional associations from
text mining. STRING interactome maps were used to search for
statistically significant enrichment of KEGG pathways.
Data availability
All stocks are available on request. Supplement Table S1 provides
details of all RNAi lines used and link to the corresponding genes in
the Flybase. Complete screen information along with larval images of
the positives is also accessible from: http://www.iiserpune.ac.in/rnai/.
Supplemental material available at figshare: https://doi.org/10.25387/
g3.12746513.
RESULTS
Overexpression of EGFR or Yki proteins in the Drosophila wing
imaginal disc produces tissue overgrowth. Under these conditions the
imaginal discs retain normal epithelial organization, but grow con-
siderably larger than normal. However, in combination with addi-
tional genetic or environmental changes, the tissue can become
neoplastic and form malignant tumors (Herranz et al. 2012b 2014;
Song et al. 2017; Eichenlaub et al. 2018). In this context, we carried
out large-scale screens using UAS-RNAi lines from the Vienna
Drosophila RNAi KK library to identify genes which would drive
hyperplastic growth to neoplastic transformation when down-regu-
lated. To facilitate screening for tumorous growth, we expressed
UAS-GFP with UAS-EGFR or UAS-Yki to allow imaginal disc size
to be scored in the intact 3rd instar larva (Figure 1A; screen design,
examples and quality controls are shown in Supplemental Figures S1
and S2).
A large panel of independent UAS-RNAi lines were tested for
their effects on tissue growth in the EGFR and Yki expression
backgrounds (Figure 1B). Of 8800 lines tested (Table S1), 74 inter-
acted with EGFR to produce tumors (1%), whereas 904 interacted
with Yki (10%) (Table S2). There was limited overlap, with only
21 RNAi lines producing tumors in both screens (Figure 1B), but we
note that some loci that would be expected to score as hits in both
screens, such as dlg, scrib and l(2)gl, were not targeted by RNAi lines
in the KK collection, and so were not tested. In a parallel screen, we
started with neoplastic tumors produced by co-expression of UAS-
EGFR and UAS-SOCS36ERNAi [Herranz et al. 2012] and asked
whether including expression of another RNAi transgene could
suppress neoplasia (Figure 1A, right panels). SOCS36E depletion
has been reported to potentiate EGFR driven tumor formation by
alleviating repression of JAK Stat activity [8]. Of 8900 lines tested
(listed in Supplemental Table S1), 32 suppressed tumor formation in
this assay (Figure 1B). Supplemental Table S2 (A) lists the genes
identified in these three screens. In previous studies, massive disc
overgrowth as in Figure 1(A) was often associated with loss of apically
localized Actin and E-Cadherin: features indicative of Epithelial
Mesenchymal Transition (EMT); and with formation of malignant
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transplantable tumors [Herranz et al. 2012b, 2014; Song et al. 2017).
Apico-basal polarity andMatrixMetalloprotease 1 (MMP1) expression
were assessed for a randomly selected subset of lines from the EGFR
and Yki screens to assess neoplastic transformation (Figure S3).
To identify the processes and pathways responsible for the in-
teraction with the screen drivers, we looked for over-representation of
biological functions among the screen positives using gene set
enrichment analysis and the KEGG, REACTOME, GO and PAN-
THER databases. Figure 2 presents the results of the enrichment
analysis as graphical interaction maps, with similar biological
processes color-coded. Edge length represents similarity between
genes associated with significantly enriched terms. Thus, similar
terms are closer together and form a community of biological process.
The genes in each cluster are shown in Figure 2 and listed in
Supplemental Table S3.
Genes that potentially modulate EGFR function during
growth control
For discs overexpressing EGFR, we observed enrichment of RNAi
lines targeting the Hippo pathway, growth signaling, and apoptosis
(Figure 2A, B). Many of the genes in the Hippo pathway act as
negative regulators of tissue growth, so their depletion by RNAi is
expected to promote growth. The Hippo pathway is known to interact
with the EGFR pathway to regulate normal developmental growth
(Ren et al. 2010; Herranz et al. 2012a; Reddy and Irvine 2013). The
Hippo pathway hits included core elements of the pathway, hpo, wts
and mats, which serve as negative growth regulators; the upstream
pathway regulators fat (an atypical cadherin) and expanded; as well as
the transcriptional corepressor grunge, which is linked to Hippo
pathway activity (Table S3). Several of these loci also contributed to
the enrichment of terms linked to apoptosis, along with pten, a
phospholipase that serves as a negative regulator of PI3K/AKT
signaling, protein kinase A-C1, Src42A, the insulin-like peptide,
ilp4, which are also linked to growth control (Table S3).
For suppression of tumors in discs overexpressing EGFR together
with SOCS36E RNAi, we observed enrichment of RNAi lines target-
ing signaling pathways related to growth, including elements of the
AKT/PI3K pathway (Figure 2E, F, Table S3). These pathways may be
required for neoplasia in this EGFR driven tumor model. Interest-
ingly, this pathway was also identified in a screen for synthetic lethals
interacting with RasV12 (Willecke et al. 2011). As would be expected,
depletion of Egfr limited tumor growth. Also enriched was a set of
genes involved in protein synthesis (Table S3). This may reflect a need
for active cellular growth machinery to support tumor growth. The
significance of genes involved in RNA splicing merits further
investigation.
Genes that potentially modulate Yki function during
growth control
For discs overexpressing Yki, RNAi lines targeting the Hippo pathway
and associated growth regulators led to tumor production (Figure 2C,
D, Table S3). These include hpo, sav, wts, mats, ft and Grunge (Gug).
Althoughwts null mutants show some loss of neuronal differentiation
and impairment of polarity (Menut et al. 2007) tumor formation
solely due to elevated Yki activity has not been observed previously in
Drosophila. It is worth noting that overexpression of YAP has been
shown to lead to neoplasia in mouse liver and intestinal epithelial
models (Dong et al. 2007; Cai et al. 2010). While most cancers appear
to result from activation/inactivation of multiple genes and pathways,
sufficient activation of the Yki or Yap can result in neoplasia.
The Hippo tumor suppressor pathway is regulated by cell polarity,
cell contact, and mechanical forces (Wada et al. 2011; Halder et al.
2012; Aragona et al. 2013) as well as by other growth signaling
pathways. The atypical Cadherin Fat mediates cell interactions and
acts upstream of the Hippo pathway. Gug is the fly ortholog of the
mammalian Atrophin/RERE proteins, and has been reported to
interact physically and genetically with Fat (Fanto et al. 2003).
Growth signaling pathways involving the sgg, pten, PKA-C1, TSC1
genes among others, were also identified. Additionally, a number of
genes linked to membrane-cytoskeleton interaction and transmem-
brane transport were found to interact, including Arf and Rab family
members. We also noted the enrichment of terms related to lipid and
general metabolism. Regulation of lipid metabolism might affect the
properties of cellular membranes. An intriguing subgroup contain
genes related to glutamatergic signaling, including the vesicular
glutamate transporter VGlut and the Eaat plasma membrane gluta-
mate transporters. This finding is of interest in light of the results of
an in vivo chemical screen which showed that that scribble mutant
RasV12 tumors are glutamine-dependent (Willoughby et al. 2013).
These tumors upregulate Yki and require Yki for tumor growth
(Doggett et al. 2011).
Another major finding from this screen is the fact that many
components of the machinery causing Promoter proximal pausing of
Figure 1 tumor formation/suppression visualized
in intact larvae (A) Larvae co-expressed UAS-GFP
with the indicated transgenes to permit visuali-
zation of the imaginal discs in the intact animal.
All samples carried the ap-Gal4 driver and UAS-
GFP. In addition, they carried either a second
copy of UAS-GFP or one of the following: UAS-
Yki, UAS-EGFR or UAS-EGFR+UAS-SOCS36ER-
NAi. (B) Table summarizing the number of RNAi
lines screened and identified in the three large-
scale screens (represents those many number of
interacting genes).
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RNA Polymerase II (such as components of the 7SK snRNAP and
NELF complexes) are when depleted, enhanced Yki-driven growth
leading to neoplastic transformation of Drosophila wing imaginal
discs (Nagarkar et al. 2020). Additional work suggested that this
phenomenon is dependent on CDK9 function and also specific to
Yki-induced growth context (Nagarkar et al. 2020).
The large number of Yki interactors could reflect greater sensi-
tivity of the screen. Alternatively, it might indicate a high false
positive rate. While this screen was in progress, Vissers et al. (Vissers
et al. 2016), reported that some of the RNAi lines from the Vienna
Drosophila RNAi KK library have the potential to produce false
positives in screens based on sensitized Hippo pathway phenotypes.
This proved to be due to the presence of a second transgene landing
site at 40D that was found in a subset of KK lines, in addition to the
30B landing site (Green et al. 2014; Vissers et al. 2016). We tested the
40D landing site strain (Vissers et al. 2016) and found that it did not
cause a tumor phenotype under the conditions used for the screen.
Nonetheless, we sampled the 40D status for a large subset of our Yki
interactors (Table S2, 734/904) and found that 45% of them had
insertions at 40D. A small survey comparing KK lines with Trip and
GD lines showed that 65% of genes for which the KK line had a 40D
site retested positive for interaction with Yki using an independent
(non-KK) transgene (15/23). The Yki-interaction screen should
therefore be viewed as a more sensitized sampling of potential
interactors, compared to the EGFR-interaction screen.
STRING interactome analyses
To view all genes identified in the three screens as one functional unit
(for the fact that they were all growth regulators in one or the other
contexts), we made use of STRING v10 (Szklarczyk et al. 2017) to
produce protein interaction maps. STRING v10 builds interaction
maps by combining experimental data (including protein interaction
data) with information about functional associations from text mining.
STRING v10 also uses information of co-occurrence, co-expression,
gene neighborhood, gene fusion, and does sequence similarity search
to predict functional interaction between proteins. An interaction
pair supported by multiple lines of evidence has higher confidence
score than other pairs.
Figure 3A shows the STRING interaction map for the genes
identified as interactors of EGFR. As noted above, Hippo pathway
(red) components were prominent among the genes identified as
cooperating with EGFR to drive tumor formation. Figure 3(B) shows
the interaction map for the genes identified as interactors of Yki.
The larger number of hits in this screen results in a more complex
Figure 2 Summary of pathway enrichment analysis of fly genes identify in the in vivo screens reported here. (A, C, E) The results of the pathway and
gene set enrichment analysis are shown as graphical interaction maps. Each node represents a significantly enriched term or pathway from the GO,
KEGG, Reactome and Panther databases (Table S3). Color-coding indicates functionally related groups of terms. Lines indicate genes shared
among different terms. (B, D, F) show the individual genes associated with functionally enriched cluster. (A, B) UAS-EGFR screen (C, D) UAS-Yki
screen (E, F) UAS-EGFR+UAS-SOCS36ERNAi screen
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Figure 3 STRING interactome analysis of potential interactors of EGFR and YKi in Drosophila. STRING analysis was performed with confidence
score of 0.7 and MCL clustering value of 2. (A) STRING Interactome of 73 fly genes identified as potential negative regulators in the context of over
expression of EGFR. 17 out of those formed molecular clusters (with PPI enrichment value of 0.000482), largest being a cluster of 6 genes, all of
which are constitutes of Fat/Hippo pathway (shown in red; FDR-1.39E-5). (B) STRING Interactome of 888 genes of identified as potential negative
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interaction map, with multiple interconnected clusters. The Hippo
pathway (red) was again prominent in the fly screen. We also noted
clusters containing elements of the ubiquitin mediated proteolysis
pathway (green) and the PI3K/TOR (blue). As noted above, the
higher sensitivity of this screen leads to the inclusion of weaker
interactors, which may add to the complexity of these interaction
maps. A focus on the stronger clusters and the interaction between
them should guide future studies. Figure 3(C) shows interaction map
for the genes identified as interactors of EGFR in the suppressor
screen (in discs overexpressing EGFR together with SOCS36E RNAi).
Among fly genes, as expected, we observed suppression of the tumor
phenotype when components of EGFR pathway are down regulated.
Human orthologs of the fly genes identified in the
three screens
To identify human orthologs for the candidate genes, we used the
DRSC Integrative Ortholog Prediction Tool, DIOPT (Version 7.1,
March 2018; www.flybase.org). DIOPT scores reflect the number of
independent prediction tools that identify an ortholog for a given
Drosophila gene. Orthology relationships are usually unambiguous
when found by most of the 12 independent prediction tools in
DIOPT. Table S2 lists the primary human orthologs (highest
weighted DIOPT score), as well as the other orthologs with a weighted
DIOPT score .2 for each of the hits in the fly screen. The primary
human ortholog was used for subsequent analysis. In cases where
multiple human orthologs had the same score, all orthologs with
highest weighted DIOPT score were used. Out of 73 EGFR positive
hits, 46 genes had one or more human orthologs, in total mapping to
50 human genes. Out of 32 SOCS positive hits 30 genes had one or
more human orthologs, in total mapping to 31 human genes. Out of
904 YAP positive hits 570 genes had one or more human orthologs, in
total mapping to 611 human genes.
To view the human orthologs in a functional context, we per-
formed a gene set enrichment analysis and the KEGG, REACTOME,
GO, PANTHER, NCI, MsigDB, BIOCARTA databases. Figure 4
presents the results of the enrichment analyses as graphical interac-
tion maps, with similar biological processes color-coded. Edge length
represents similarity between genes associated with significantly
enriched terms. Thus, similar terms are closer together and form a
community of biological processes. The genes in each cluster are
shown in Figure 4 and listed in Supplemental Table S4. Because the
enrichment analysis is highly sensitive to the number of orthologs for
each of the fly genes, we used the minimal set consisting of only the
primary human orthologs.
Hippo pathway components were enriched among the orthologs
cooperating with EGFR to drive tumor formation (Figure 4A, B;
Table S3). Two of these, LATS1 and STK3, also contributed to
enrichment for a term linked to protein turnover. Regulation of
protein turnover is an important mechanism for controlling the
activity of a number of Hippo pathway components. For the screen
for suppression of tumors in discs overexpressing EGFR together with
SOCS36E RNAi, we observed enrichment of orthologs targeting
growth signaling pathways, protein synthesis and mRNA splicing
(Figure 4E, F, Table S4), similar to what was seen for the fly gene set
analysis. We also observed enrichment of pathways related to protein
folding and molecular chaperones, in the human gene set. For the Yki
screen, the human ortholog set was enriched for terms related to
general metabolism, and membrane transport, as well as growth
signaling, and other signaling pathways, including genes involved in
protein turnover (Figure 4C, D).
METABRIC Analysis
We also studied gene expression levels in cancer patients by system-
atically querying METABRIC (Pereira et al. 2016) a large database on
breast cancer. We chose this as breast cancer is an epithelial cancer
and the distribution of treatment-naïve samples from very early to
late stages are well characterized. More importantly, gene expression
patterns have been well studied at genomic level for all stages of the
cancer. For each of the human orthologs of the genes identified in the
Yki screen, we examined how their expression levels (low levels,
median levels and high levels) are correlated to clinical parameters/
attributes such as months of disease-free survival, early vs. old age of
the patients at diagnosis, Lymph node status at diagnosis, tumor
grade III or above at diagnosis, early vs. late stages of cancer at
diagnosis and small vs. large tumors at diagnosis. Total 365 human
orthologs showed significant correlation to disease-free survival.
Among them 186 were associated with their low levels of expression
and 179 with high levels of expression (see Supplement Table S4 and
Supplemental_Information_METABRIC analysis). The fact that
higher levels of expression correlate to aggressive tumors suggest that
they are potential growth promoters, while their fly homologs were
identified as potential tumor suppressors in our screen. This discrep-
ancy could be due tomore complex nature of growth control in human,
wherein a conserved pathway may have different outcomes in different
contexts. Expression levels of 76 genes also showed strong correlations
to the three clinical parameters as listed above (see Supplement Table
S4 and Supplemental_Information_METABRIC analysis) indicating
their critical role in growth control and impairment in their expression
causing tumorous growth. Taken together, the positive hits in these
screens would be useful for studies on growth control in development
model organisms and in the context of cancer in human.
DISCUSSION
The Hippo pathway has emerged from this study as the single most
important pathway limiting tumor formation in Drosophila. Increas-
ing Yki activity by depletion of upstream negative regulators pro-
moted tumor formation in both the EGFR and Yki hyperplasia
models. Yki controls tissue growth by promoting cell proliferation
and by concurrently inhibiting cell death through targets including
Diap1, cycE and bantam miRNA (Tapon et al. 2002; Huang et al.
2005; Nolo et al. 2006; Thompson and Cohen 2006; Wu et al. 2008).
The central role of the Hippo pathway as an integrator of other
growth-related signals may also contribute to the abundance of tumor
suppressors associated with Yki-driven growth (Harvey et al. 2013;
Richardson and Portela 2017, 2018). Mis-regulation of this pathway
also contributes to tumor formation in mouse models (Yu et al. 2015).
The potential of Yki/YAP expression to drive cellular transfor-
mation has been highlighted by studies of primary human cells in
regulators in the context of over expression of Yki. 228 of those formed a single cluster with PPI enrichment value 1.4E-06. Components of Fat/
Hippo pathway (red: FDR-0.00076) and Autophagy genes (blue: FDR-0.0241) are enriched in this cluster. (C) STRING Interactome of 32 fly genes
identified as potential oncogenes in the context of SOCS suppression. 27 out of those formed molecular clusters (with PPI enrichment value of
0.0122), largest being a cluster of 14 genes. A smaller cluster comprising of EGFR and DrK were enriched in Dorso-ventral axis formation (shown in
purple: FDR-0.0089).
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culture, which have shown that YAP expression is both necessary and
sufficient to confer a transformed phenotype involving anchorage
independent growth and the ability to form tumors in xenograft
models (Hong et al. 2014; Nguyen et al. 2014). We therefore consider
it likely that the consequence of Yki overexpression predispose the
tissue to transformation, allowing identification of a richer repertoire
of cooperating factors. Indeed, YAP overexpression has been causally
linked to formation of specific human tumors (Kapoor et al. 2014;
Shao et al. 2014). The Hippo pathway has also been implicated in
tumor formation resulting from cytokinesis failure (Ganem et al.
2014) and this has recently been linked to Yki-mediated regulation of
string (CDC25) expression (Gerlach et al. 2018). The sensitivity of
Yki-expressing tissue to tumor formation might be explained by the
finding that Yki promotes cell cycle progression at both the G1-S
transition (through regulation of cycE (Huang et al. 2005) and at the
G2-M transition through regulation of string. In contrast, mitogens
and growth factors such as EGFR typically induce growth by pro-
moting G1-S, and therefore remain somewhat constrained by the
G2-M checkpoint.
We have analyzed in more detail one group of genes, all related
to regulating promoter proximal pausing of RNA Poly II, identified
in this screen to validate the importance of the repertoire of genes
provided here. We have observed that Yki-driven growth is limited by
the pausing of RNA Pol II, release of which is controlled by potential
tumor suppressor genes (Nagarkar et al. 2020).
While our manuscript was in preparation, another group reported
an RNAi screen to identify loci cooperating in tumorigenesis driven
by expression in eye discs of the oncogenic activated mutant form of
Ras (Zoranovic et al. 2018). We note that the activated Ras RNAi
screen produced over 900 hits, compared with 74 for our EGFR
screen, suggesting that the Ras screen was considerably more sensi-
tized. We were surprised to note that there was almost no overlap
between the two screens with only 3 hits in common: Elongin B,
CG7966 and CG7313. This suggests that the genetic interactions
required to promote tumorigenesis in the context of expression of
an activated mutant form of RAS are distinct from those required to
promote tumorigenesis in the context of native EGRF overexpression.
And perhaps, the differences between the tissue contexts (eye discs
in (Zoranovic et al. 2018) vs. wing discs in our screen). It will be of
interest, in future, to learn whether this distinction holds true for
factors promoting tumor formation in human cancers that depend on
EGFR overexpression vs. those dependent on Ras mutants.
To conclude, the results reported here provide an extensive
assessment of the genes that can serve as negative regulators of
Figure 4 Summary of pathway enrichment analysis of human orthologs (A, C, E) The results of the pathway and gene set enrichment analysis are
shown as enrichment maps. Each node represents a significantly enriched term or pathway from the GO, KEGG, Reactome and PANTHER, NCI,
MsigDB, BIOCARTAdatabases (Table S3). Color-coding indicates functionally related groups of terms. Lines indicate genes shared amongdifferent
terms. (B, D, F) show the individual genes associated with functionally enriched cluster. (A, B) UAS-EGFR screen (C, D) UAS-Yki screen (E, F)
UAS-EGFR+UAS-SOCS36ERNAi screen.
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growth that can contribute to the formation of neoplastic tumors
in vivo in Drosophila. In addition to finding genes linked to
known growth control pathways, a number of novel connections
to Yki and EGFR driven tissue growth have been identified, which
merit further investigation in the Drosophila genetic model.
Exploring the potential relevance of genes identified in this
manner to human cancer will involve assessing the correlation
of candidate gene expression with clinical outcome across a broad
range of cancers (e.g., (Andrejeva et al. 2018; Eichenlaub et al.
2018)), as a starting point to identify biomarkers as well as novel
candidate drug targets.
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